IBRX
$8.47-0.35 (-3.97%)
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases.
Recent News
How Investors May Respond To ImmunityBio (IBRX) Securing First Asian Approval For ANKTIVA Via Macau Pathway
ImmunityBio recently reported that Macau’s Pharmaceutical Administration Bureau approved ANKTIVA (nogapendekin alfa inbakicept-pmln) plus BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, mirroring its existing U.S. indication. This first authorization for ANKTIVA in Asia highlights ImmunityBio’s use of reliance-based reviews on FDA and EMA decisions to broaden global access for its lead therapy. We’ll now examine how ANKTIVA’s first Asian...
Jim Cramer on ImmunityBio: “That Stock Is Part of the Magical Thinking Era”
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the stocks mentioned during the show, as we cover everything Jim Cramer said about the oversold market. When a caller inquired about the stock during the lightning round, Cramer said: ImmunityBio had a big cross of a huge amount of stock, but at the end, I don’t know where […]
BTIG Sees Upside in ImmunityBio, Inc. (IBRX), Cites Strong 2026 ANKTIVA Sales Growth
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best Robinhood stocks on this list. TheFly reported on March 11 that BTIG gave IBRX a Buy rating and assigned a $13 price target. The firm pointed to the stock’s strong performance in 2026, supported by rapid year-over-year growth in U.S. ANKTIVA sales, conditional marketing authorization in the European Union, and NSCLC approval […]
ImmunityBio (IBRX) Resubmits sBLA to FDA for ANKTIVA in Papillary Bladder Cancer
ImmunityBio Inc. (NASDAQ:IBRX) is one of the most buzzing stocks to buy with the highest upside potential. On March 9, ImmunityBio announced the resubmission of its sBLA to the FDA for ANKTIVA in combination with Bacillus Calmette-Guérin/BCG. This filing specifically targets patients with BCG-unresponsive non-muscle invasive bladder cancer/NMIBC who present with papillary disease. The resubmission […]
ImmunityBio Highlights ANKTIVA Surge, FDA Papillary Filing and Key 2026 Milestones at Conference
ImmunityBio (NASDAQ:IBRX) CEO Richard Adcock used a presentation at the Citizens Life Sciences Conference to outline the company’s commercial progress with its lead product ANKTIVA and to highlight multiple upcoming regulatory and clinical milestones across bladder cancer, lung cancer, and earlier-s